Posted: 29 November 2023
Rhythm Biosciences Ltd is pleased to provide an update on its cancer diagnostics technology platform expansion program in lung cancer. As previously announced, together with the Baker Institute, Rhythm has identified a 5 biomarker combination that exhibits an effective correlation with various stages of lung cancer.
The preliminary assessment of 17 biomarkers was performed by the Baker Institute in a “research use only” feasibility immunoassay study to evaluate these blood-based biomarkers from 70 lung cancer patients and 71 healthy volunteers. This preliminary R&D has identified an important biomarker combination that can distinguish between patients with lung cancer and healthy controls, with >85% sensitivity and >90% specificity.
These encouraging results warrant confirmation in a larger population and justify the continuation and advancement of the project. Therefore, verification of these results would support the case for investments in a new R&D program to develop, validate, clinically evaluate the performance of the biomarkers, and translate these results into a commerifcally scalable, proprietary blood test to detect lung cancer early when it is most responsive to potentially curative treatments.
